The survey was completed by 540 nurses, predominantly staff-level registered nurses (78%) and, to a much lesser extent, nurse managers (8%) and nurse educators (8%). Most participating nurses (87%) ...

The problems with overfilled Hospira Carpuject syringes is far more extensive than first suspected, but instead of ordering a recall, which would create some immediate shortages, the FDA is leaning on ...

For the third time in six months, Pfizer (PFE) is having difficulty manufacturing certain prefilled syringes of opioid painkillers — and the ongoing supply problems are upsetting hospitals around the ...

An investigation into user complaints of overfilled Carpuject syringes led Hospira ($HSP) to realize manufacturing problems with overfills were far more extensive ...

UNDATED - Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe ...

Hospira announced a nationwide voluntary recall of one lot of Morphine Sulfate injection, 4mg/mL, due to a customer report of two Carpujects syringes containing more than the 1mL labeled fill volume.

The company is recalling two lots of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system due to particulate matter on the syringe plunger.

Pfizer notified customers Jan. 31 it is having difficulty making certain prefilled syringes of opioid painkillers — marking the third time in six months the company has encountered manufacturing ...

The batch was distributed between August 14, 2018 and September 5, 2018. Two lots of naloxone hydrochloride injections, USP have been recalled by Hospira, Inc., due to concerns regarding the presence ...

ISMP has long endorsed the use of unit dose syringes of injectable drugs, including Carpujects, as a safe practice. If Carpuject cartridges are stocked in patient care units, to ensure proper use ISMP ...